Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The medical claim provided (indication as adjunct to diet/exercise for adults with type 2 diabetes; should not be used in type 1 diabetes) is directly supported by the supplied label excerpts, with no contradictions.
Category Scores
Accurate Statements
JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Label section 1 INDICATIONS AND USAGE: “indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”
JANUVIA should not be used in patients with type 1 diabetes.
Label section 1 INDICATIONS AND USAGE: “Limitations of Use… JANUVIA should not be used in patients with type 1 diabetes.”
Unsupported Statements
JANUVIA has not been studied in patients with a history of pancreatitis; it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA.
Unsupported as a distinct claim because it appears only in the provided label excerpts, but the evaluation target question contained only the indication/limitation claim; treat as not evaluated for alignment with the specific claim focus.
Contradictions
Important Omissions
No assessment was provided for dosage/administration, contraindications beyond the type-1 limitation, boxed warnings (if any), drug interactions, or monitoring—however these were not part of the stated claim being evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements concern on-label indication and a key limitation (no type 1 use) and are supported by the provided label excerpts, with no contradictions detected.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The supplied label excerpt includes pancreatitis limitation text, but the claim-evaluation focus appears limited to indication/type-1 use; ensure scope alignment when evaluating additional label content.
Suggested Improvement
Limit claim-by-claim assessment strictly to the statements requested for evaluation, or explicitly include/confirm which additional label statements are within scope.